argenx SE
(NASDAQ : ARGX)

( )
ARGX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MDCOThe Medicines Co.
-0.18%84.0720.1%$615.29m
AMRNAmarin Corp. Plc
-1.81%22.811.7%$318.52m
VRXValeant Pharmaceuticals International, Inc.
0.29%29.3314.1%$172.58m
ARQLArQule, Inc.
1.23%20.200.6%$138.24m
SAGESAGE Therapeutics, Inc.
8.50%68.678.6%$117.60m
BHCBausch Health Cos., Inc.
0.29%29.330.0%$108.40m
ICPTIntercept Pharmaceuticals, Inc.
3.90%119.3616.9%$94.85m
JAZZJazz Pharmaceuticals Plc
-1.29%148.122.3%$90.55m
GWPHGW Pharmaceuticals Plc
0.41%102.886.2%$82.61m
PRGOPerrigo Co. Plc
0.22%53.816.8%$64.79m
AXSMAxsome Therapeutics, Inc.
-1.40%48.072.0%$59.48m
ICLRICON plc
-0.29%161.734.2%$43.16m
HZNPHorizon Therapeutics Plc
0.88%32.256.6%$42.85m
UTHRUnited Therapeutics Corp.
-0.58%92.4914.3%$35.77m
CTLTCatalent, Inc.
-1.71%52.182.4%$31.61m

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.